AU2014340114B2 - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents

Compounds for use in prevention and treatment of neurodegenerative diseases and pain Download PDF

Info

Publication number
AU2014340114B2
AU2014340114B2 AU2014340114A AU2014340114A AU2014340114B2 AU 2014340114 B2 AU2014340114 B2 AU 2014340114B2 AU 2014340114 A AU2014340114 A AU 2014340114A AU 2014340114 A AU2014340114 A AU 2014340114A AU 2014340114 B2 AU2014340114 B2 AU 2014340114B2
Authority
AU
Australia
Prior art keywords
pain
adenosine
compound
group
tdp43
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014340114A
Other languages
English (en)
Other versions
AU2014340114A1 (en
Inventor
Chih-Cheng Chen
Yijuang Chern
Jim-Min Fang
Nai-Kuei Huang
Chun-Jung Lin
Jung-Hsin Lin
Yun-Lian Lin
Benjamin Pang-hsien TU
Hung-Li WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of AU2014340114A1 publication Critical patent/AU2014340114A1/en
Application granted granted Critical
Publication of AU2014340114B2 publication Critical patent/AU2014340114B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2014340114A 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain Active AU2014340114B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
US61/894,699 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (2)

Publication Number Publication Date
AU2014340114A1 AU2014340114A1 (en) 2016-05-26
AU2014340114B2 true AU2014340114B2 (en) 2018-10-18

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014340114A Active AU2014340114B2 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Country Status (14)

Country Link
US (1) US10301348B2 (enExample)
EP (1) EP3060566B1 (enExample)
JP (1) JP6534997B2 (enExample)
KR (1) KR102313314B1 (enExample)
CN (1) CN106414456B (enExample)
AU (1) AU2014340114B2 (enExample)
BR (1) BR112016008901B1 (enExample)
CA (1) CA2927699C (enExample)
IL (1) IL245103B (enExample)
MX (1) MX367707B (enExample)
RU (1) RU2695358C2 (enExample)
SG (1) SG11201603063WA (enExample)
WO (1) WO2015061426A1 (enExample)
ZA (1) ZA201603118B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792261A1 (ru) * 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
US11753432B2 (en) 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
CN119384282A (zh) * 2022-02-10 2025-01-28 周美吟 治疗脊髓损伤的方法及用于其中的组合物
CN119630406A (zh) * 2022-07-07 2025-03-14 周美吟 治疗思觉失调症的方法及用于其中的组合物
CN120548177A (zh) * 2022-12-29 2025-08-26 周美吟 治疗睡眠障碍的方法及用于其中的组合物
WO2024196760A1 (en) * 2023-03-17 2024-09-26 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064340A1 (en) * 2009-11-13 2012-05-18 Academia Sinica Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
JP6208693B2 (ja) 2012-02-09 2017-10-04 ブランドバンプス,エルエルシー 改良されたグリップを有する装飾された検知可能な警告パネル

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064340A1 (en) * 2009-11-13 2012-05-18 Academia Sinica Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Also Published As

Publication number Publication date
MX2016005174A (es) 2016-08-11
BR112016008901B1 (pt) 2022-08-23
US10301348B2 (en) 2019-05-28
NZ719740A (en) 2021-02-26
CA2927699A1 (en) 2015-04-30
EP3060566A4 (en) 2017-06-14
JP2016535019A (ja) 2016-11-10
WO2015061426A1 (en) 2015-04-30
RU2016118282A (ru) 2017-11-28
EP3060566A1 (en) 2016-08-31
RU2016118282A3 (enExample) 2018-06-18
ZA201603118B (en) 2019-04-24
CN106414456A (zh) 2017-02-15
CN106414456B (zh) 2018-12-14
CA2927699C (en) 2022-07-05
BR112016008901A2 (pt) 2020-05-12
US20160264613A1 (en) 2016-09-15
RU2695358C2 (ru) 2019-07-23
IL245103B (en) 2019-02-28
IL245103A0 (en) 2016-06-30
KR20160086852A (ko) 2016-07-20
AU2014340114A1 (en) 2016-05-26
MX367707B (es) 2019-09-03
EP3060566B1 (en) 2018-09-05
KR102313314B1 (ko) 2021-10-19
SG11201603063WA (en) 2016-05-30
JP6534997B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
JP7661228B2 (ja) オリゴヌクレオチド組成物及びその方法
EP3781564B1 (en) Pyridazine derivatives for the treatment of cancer
EP3719125B1 (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
AU2021230473A1 (en) Oligonucleotide compositions and methods thereof
EP3060566B1 (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
CN110996968A (zh) 寡核苷酸组合物及其方法
CN113614230B (zh) 核酸、药物组合物与缀合物及制备方法和用途
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP2022537581A (ja) Ppm1阻害剤およびその使用方法
TW201605881A (zh) 酸性α葡萄糖苷酶之反義股誘導之外顯子2包含
JP2020537688A (ja) 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
AU2024338611A1 (en) Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto
SA521421104B1 (ar) أوليجومرات تجاوز إكسون للحثل العضلي
TW201910514A (zh) 纖維化治療劑
KR20260022373A (ko) 변형된 unc13a 올리고뉴클레오티드
TWI668007B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
TW201617356A (zh) 用於預防及治療神經退化疾病及疼痛之化合物
RU2847121C2 (ru) Композиции на основе олигонуклеотидов и способы, связанные с ними
CN116528878A (zh) 使用基因转录物调控剂治疗神经学疾病
HK40027139A (en) Oligonucleotide compositions and methods thereof
HK40056327A (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)